Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cancer Genetics Inc (CGIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,496
  • Shares Outstanding, K 27,750
  • Annual Sales, $ 29,120 K
  • Annual Income, $ -20,880 K
  • 36-Month Beta 1.04
  • Price/Sales 1.03
  • Price/Cash Flow N/A
  • Price/Book 1.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.16
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.87 +36.39%
on 08/29/18
1.20 -1.12%
on 09/18/18
+0.12 (+10.90%)
since 08/21/18
3-Month
0.85 +39.60%
on 07/05/18
1.20 -1.12%
on 09/18/18
+0.20 (+19.86%)
since 06/21/18
52-Week
0.82 +44.36%
on 05/10/18
3.50 -66.10%
on 10/31/17
-1.71 (-59.08%)
since 09/21/17

Most Recent Stories

More News
Cancer Genetics Offers Oncomine Comprehensive Assay to Drive Clinical Trials

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the successful CLIA validation...

CGIX : 1.18 (+4.42%)
Chardan Advises NovellusDX in Cross-Border Biotech Merger

Chardan, a global investment bank, announced today that the firm acted as exclusive financial advisor to NovellusDX, Ltd., a leader in functional genomics, for the firm's agreement to merge with a newly...

CGIX : 1.18 (+4.42%)
Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, and NovellusDx, Ltd., a leader in functional...

CGIX : 1.18 (+4.42%)
Cancer Genetics Reports Second Quarter 2018 Financial Results and Provides Strategic Business Updates

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced financial and operating...

CGIX : 1.18 (+4.42%)
Cancer Genetics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Cancer Genetics, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern Time....

CGIX : 1.18 (+4.42%)
Cancer Genetics to Report Second Quarter 2018 Financial Results on August 14, 2018

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it will release its financial results for the...

CGIX : 1.18 (+4.42%)
Cancer Genetics Closes $2.625 million Convertible Note Financing

Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the closing of a $2.625 million convertible note financing...

CGIX : 1.18 (+4.42%)
Cancer Genetics Strengthens Management Team with Appointment of Michael McCartney as Chief Commercial Officer

Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the appointment Michael McCartney as the Company's Chief...

CGIX : 1.18 (+4.42%)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cancer Genetics, Inc. (CGIX) and Lead Plaintiff Deadline - June 4, 2018

NEW YORK, NY / ACCESSWIRE / May 16, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Cancer Genetics, Inc.("Cancer Genetics" or the "Company") (NASDAQ:...

CGIX : 1.18 (+4.42%)
DEADLINE ALERT: Shareholder Class Action Filed Against Cancer Genetics, Inc. - CGIX

RADNOR, PA / ACCESSWIRE / May 15, 2018 / Kaskela Law LLC reminds Cancer Genetics, Inc. (NASDAQ: CGIX) ("Cancer Genetics" or the "Company") shareholders that a class action lawsuit has been filed on behalf...

CGIX : 1.18 (+4.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade CGIX with:

Business Summary

Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated...

See More

Key Turning Points

2nd Resistance Point 1.19
1st Resistance Point 1.16
Last Price 1.18
1st Support Level 1.09
2nd Support Level 1.05

See More

52-Week High 3.50
Fibonacci 61.8% 2.48
Fibonacci 50% 2.16
Fibonacci 38.2% 1.84
Last Price 1.18
52-Week Low 0.82

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar